scholarly journals Heterologous SARS‐CoV ‐2 Vaccinations in Patients with B‐cell Lymphoid Malignancies

2021 ◽  
Author(s):  
Chaitra Ujjani ◽  
Alexander L. Greninger ◽  
Mazyar Shadman ◽  
Joshua A. Hill ◽  
Ryan C. Lynch ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoid Malignancies

scholarly journals Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment

2019 ◽  
Vol 291 (1) ◽  
pp. 190-213 ◽  
Author(s):  
Ryan M. Young ◽  
James D. Phelan ◽  
Wyndham H. Wilson ◽  
Louis M. Staudt
Keyword(s):  
B Cell ◽  
Cell Receptor ◽  
B Cell Receptor ◽  
Receptor Signaling ◽  
Lymphoid Malignancies ◽  
Improve Treatment ◽  
B Cell Receptor Signaling ◽  
Cell Receptor Signaling

Mutations known from B-cell lymphoid malignancies are not found in CD34+ stem cells from patients with lymphoma

2021 ◽  
pp. 1-4
Author(s):  
Simon Husby ◽  
Francesco Favero ◽  
Francisco G. Rodriguez-Gonzalez ◽  
Lesley A. Sutton ◽  
Eva K. Haastrup ◽  
...  
Keyword(s):  
Stem Cells ◽  
B Cell ◽  
Lymphoid Malignancies

scholarly journals The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia

2016 ◽  
Vol 7 (6) ◽  
pp. 321-329 ◽  
Author(s):  
Valentín Ortíz-Maldonado ◽  
Pablo Mozas ◽  
Julio Delgado
Keyword(s):  
Clinical Trials ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Mitochondrial Pathway ◽  
Therapeutic Agents ◽  
Lymphocytic Leukemia ◽  
Hallmarks Of Cancer ◽  
Lymphoid Malignancies

B-cell lymphoma 2 (BCL2)-type proteins are key regulators of the intrinsic or mitochondrial pathway for apoptosis. Since escape from apoptosis is one the main ‘hallmarks of cancer’, BCL2 inhibitors have emerged as promising therapeutic agents for diverse lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). Multiple clinical trials have shown efficacy of these agents in patients with relapsed/refractory disease with a favorable toxicity profile. Moreover, some clinical trials indicate that combination with monoclonal antibodies and other novel agents may enhance their effect.

scholarly journals NF-κB2 mutation targets TRAF1 to induce lymphomagenesis

Blood ◽  
2007 ◽  
Vol 110 (2) ◽  
pp. 743-751 ◽  
Author(s):  
Baochun Zhang ◽  
Zhe Wang ◽  
Tai Li ◽  
Erdyni N. Tsitsikov ◽  
Han-Fei Ding
Keyword(s):  
Transgenic Mice ◽  
B Cell ◽  
Apparent Effect ◽  
Antiapoptotic Protein ◽  
Lymphoid Malignancies ◽  
Targeted Expression ◽  
Antiapoptotic Activity ◽  
B Cell Homeostasis ◽  
Cytokine Deprivation

Abstract The NF-κB2 gene is recurrently mutated in human lymphoid malignancies. However, a causal relationship between NF-κB2 mutation and lymphomagenesis has not been established. It is also unclear how the mutation may lead to lymphoid malignancies. We report the generation of transgenic mice with targeted expression of p80HT, a lymphoma-associated NF-κB2 mutant, in lymphocytes. The transgenic mice display a marked expansion of peripheral B cell populations and develop predominantly small B cell lymphomas. p80HT expression has no apparent effect on the proliferation of B cells, but renders them specifically resistant to apoptosis induced by cytokine deprivation and mitogenic stimulation. Lymphocytes and lymphoma cells from p80HT mice express high levels of TRAF1, an antiapoptotic protein also implicated in lymphoid malignancies. p80HT binds the TRAF1 promoter in vivo and activates TRAF1 transcription. Moreover, TRAF1 knockdown abrogates the antiapoptotic activity of p80HT and TRAF1 deficiency reestablishes B cell homeostasis in p80HT mice. These findings demonstrate NF-κB2 mutation as an oncogenic event in vivo and suggest a molecular pathway for TRAF1 activation in the pathogenesis of lymphomas.

Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models

Blood ◽  
2011 ◽  
Vol 118 (3) ◽  
pp. 660-669 ◽  
Author(s):  
Maria Teresa Sabrina Bertilaccio ◽  
Giorgia Simonetti ◽  
Antonis Dagklis ◽  
Martina Rocchi ◽  
Tania Veliz Rodriguez ◽  
...  
Keyword(s):  
Immune Response ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Adaptive Immune Response ◽  
Lymphocytic Leukemia ◽  
Fine Tuning ◽  
Terminal Phase ◽  
Lymphoid Malignancies ◽  
History Of ◽  
Molecular Patterns

Abstract Inflammation is involved in the initiation and progression of several chronic lymphoid malignancies of B-cell type. Toll-like receptors (TLR) are transmembrane inflammatory receptors that on recognition of pathogen-associated molecular patterns trigger an innate immune response and bridge the innate and adaptive immune response by acting as costimulatory signals for B cells. Fine tuning of TLR and IL-1R–like (ILR) activity is regulated by TIR8 (SIGIRR), a transmembrane receptor of the TLR/ILR family which inhibits other family members. To test the hypothesis that TLR and/or ILR may play a role in the natural history of chronic B-cell tumors, we crossed Eμ-TCL1 transgenic mice, a well established model of chronic lymphocytic leukemia (CLL), with mice lacking the inhibitory receptor TIR8 that allow an unabated TLR-mediated stimulation. We here report that in the absence of TIR8 the appearance of monoclonal B-cell expansions is accelerated and mouse life span is shortened. The morphology and phenotype of the mouse leukemic expansions reproduce the progression of human CLL into an aggressive and frequently terminal phase characterized by the appearance of prolymphocytes. This study reveals an important pathogenetic implication of TLR in CLL development and progression.

scholarly journals Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients

2019 ◽  
Vol 6 (9) ◽  
Author(s):  
Caroline Protin ◽  
Florence Abravanel ◽  
Laurent Alric ◽  
Suzanne Tavitian ◽  
Lucie Obéric ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Virus Infection ◽  
B Cell ◽  
Viral Hepatitis ◽  
Hepatitis E Virus ◽  
Kinase Inhibitor ◽  
Hepatitis E ◽  
Single Center ◽  
Lymphoid Malignancies ◽  
Single Center Experience

Abstract Ibrutinib is an oral first-in-class Bruton’s tyrosine kinase inhibitor approved for the therapy of various B-cell lymphoid malignancies. Among ibrutinib-related infections, viral hepatitis are poorly described. We report our single-center experience with 4 cases of chronic hepatitis E virus infection and their management with ribavirin.

scholarly journals Molecular characterization of centerin, a germinal centre cell serpin

2007 ◽  
Vol 405 (3) ◽  
pp. 489-494 ◽  
Author(s):  
Melinda A. Paterson ◽  
Anita J. Horvath ◽  
Robert N. Pike ◽  
Paul B. Coughlin
Keyword(s):  
B Cell ◽  
Serine Protease ◽  
Molecular Characterization ◽  
Good Prognosis ◽  
Germinal Centre ◽  
Lymphoid Malignancies ◽  
B Cell Maturation ◽  
Absolute Requirement

Centerin [SERPINA9/GCET1 (germinal centre B-cell-expressed transcript 1)] is a serpin (serine protease inhibitor) whose expression is restricted to germinal centre B-cells and lymphoid malignancies with germinal centre B-cell maturation. Expression of centerin, together with bcl-6 and GCET2, constitutes a germinal centre B-cell signature, which is associated with a good prognosis in diffuse large B-cell lymphomas, but the molecular basis for this remains to be elucidated. We report here the cloning, expression and molecular characterization of bacterial recombinant centerin. Biophysical studies demonstrated that centerin was able to undergo the ‘stressed to relaxed’ conformational change which is an absolute requirement for protease inhibitory activity. Kinetic analysis showed that centerin rapidly inhibited the serine protease trypsin (ka=1.9×105 M−1·s−1) and also demonstrated measurable inhibition of thrombin (ka=1.17×103 M−1·s−1) and plasmin (ka=1.92×103 M−1·s−1). Centerin also bound DNA and unfractionated heparin, although there was no functionally significant impact on the rate of inhibition. These results suggest that centerin is likely to function in vivo in the germinal centre as an efficient inhibitor of a trypsin-like protease.

scholarly journals Minimally Invasive Diagnosis of Secondary Intracranial Lymphoma

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
A. P. McClement ◽  
G. M. Healy ◽  
C. E. Redmond ◽  
E. Stocker ◽  
G. Connaghan ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Minimally Invasive ◽  
B Cell ◽  
High Mortality ◽  
Central Nervous System Relapse ◽  
Poor Survival ◽  
Lymphoid Malignancies ◽  
Intracranial Recurrence ◽  
Large B Cell

Diffuse large B cell lymphomas (DLBCL) are an aggressive group of non-Hodgkin lymphoid malignancies which have diverse presentation and can have high mortality. Central nervous system relapse is rare but has poor survival. We present the diagnosis of primary mandibular DLBCL and a unique minimally invasive diagnosis of secondary intracranial recurrence. This case highlights the manifold radiological contributions to the diagnosis and management of lymphoma.

Sign in / Sign up

Export Citation Format

Share Document